Use of TNF-alpha inhibitor for treatment of psoriasis

  • US 8,906,373 B2
  • Filed: 04/30/2014
  • Issued: 12/09/2014
  • Est. Priority Date: 07/19/2002
  • Status: Active Grant
First Claim
Patent Images

1. A method of treatment of psoriasis in a patient with moderate to severe active psoriatic arthritis (PsA), comprising subcutaneously administering to said patient 40 mg adalimumab every other week, wherein said patient has ≧

  • 3 swollen and ≧

    3 tender joints prior to the treatment and has failed NSAID therapy, and wherein said patient achieves a 90% reduction of the Psoriasis Area and Severity Index Score (PASI

         90) at week 24 of the treatment.

View all claims

    Thank you for your feedback